Cancer Immunotherapy
We want to develop anti-cancer cellular therapies based on genetic reprogramming of cytotoxic immune-effectors, empowering their ability to recognize a specific target simultaneously prolonging their action.
Current research:
- Cytotoxic T-Lymphocytes (CTL) with gene modification carrying Chimeric Antigen Receptor (CTL-CAR)
- CTL-CAR potential in neuroblastoma and glioma pre-clinical and clinical models
- Identification of tumour-associated antigens as novel targets for new CAR immunotherapies in different neoplasms
Laboratory expertise:
- Isolation and characterization of human CTL
- CTL ex vivo amplification by introducing both standard and innovative culture conditions
- Plasmid vector construction, cell modification and protein expression
- Immunophenotyping and FACS sorting
- Cytotoxicity assays
- Neuroblastoma and Glioma xenotransplantation models
- Time lapse microscopy
- Multiparametric histological analyses and microscopy
- Safety profile analyses
